Symptom Duration Shortened by Early Initiation of Nebulized Isomerized Linoleic Acid (LA) for Outpatient Treatment of COVID-19.

With a total of 6 patients, albeit a small number, we find a statistically significant correlation between 'when beginning nebulizing treatment with LA' and the 'length of reported COVID-related symptoms' (p<0.01; r=0.965). We report the clinical course of four COVID-19 cases, 2 probable cases, and 2 close contacts treated with nebulized Isomerized Linoleic Acid (LA). Comorbidity ranged from none to high risk. No side effects were reported by this group of patients. Isomerized LA was completely effective in the small sample of close contacts. Early treatment onset shortened the duration of symptoms. We define symptom duration as the total length of symptoms that were reported during the course of illness. All patients reported a total resolution of symptoms after treatment, except for one who started nebulized LA 4 days after onset of symptoms of infection, who reported some lingering fatigue. The case study findings could pose a potential timeline for future research into when nebulized LA treatment would be most effective. Complications of COVID-19 appeared to be affected by early onset of treatment. Since global case counts and deaths attributed to COVID-19 are continuing to rise, there needs to be an effective, low cost outpatient therapeutic available. Nebulized LA provides the opportunity for just that, a safe, low cost, and effective option for outpatient COVID-19 treatment. We hope this case study will prompt further and much needed research into COVID-19 outpatient treatment.